Friday, October 13, 2017 9:31:06 AM
By Rachel Graf
Law360, New York (October 12, 2017, 1:56 PM EDT) -- Three pharmaceutical companies involved in a $1 billion patent infringement suit over a quality control test for a generic blood thinner contested each other’s dueling bids for post-trial relief Wednesday — including judgment or a new trial — after a jury found the patent was infringed but the claims were nonetheless invalid.
Momenta Pharmaceuticals and Sandoz Inc., which alleged the patent infringement, argued that Amphastar Pharmaceuticals' request for a ruling that it hadn’t infringed U.S. Patent Number 7,575,886 does not reflect the evidence that was presented at...
Needs subscription -
https://www.law360.com/trials/articles/973666/trio-of-pharma-cos-fight-post-trial-bids-in-1b-patent-row
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM